PPT1 / Palmitoyl-protein thioesterase 1 · IHC design guide

Design Immunohistochemistry for PPT1

PPT1 has a lysosomal location and can be secreted (UniProt). This paraffin IHC guide uses its general lysosomal tissue profile (HPA tissue IHC) to frame fixation and staining interpretation.

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for PPT1 (IHC for PPT1): expected localisation Lysosomal localization expected (UniProt), antibody M02690, validated IHC image, and IHC protocol steps — Printable **PPT1** IHC protocol sheet — expected localisation Lysosomal localization expected (UniProt), antibody M02690, controls and protocol steps. Open the full PPT1 IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

PPT1 Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Lysosomal localization expected (UniProt)
	Staining pattern	General lysosomal staining across tissues (HPA tissue IHC)
	Antigen retrieval	EDTA pH 8.0 HIER, heat-mediated (datasheet M02690)
	Positive control ⓘ	Adrenal gland+4 more · see all
	Negative control ⓘ	Adipose tissue+3 more · see all

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep fixation consistent across sections (standard IHC practice; not target-specific). Selected-image fixative and duration unreported (datasheet M02690); verify before use.
	Caveat	Secreted PPT1 may contribute extracellular staining (UniProt)
	Regulation	No induction cue in the supplied record (UniProt)
	Isoform / epitope	2 isoforms; signal peptide cleaved; epitopes unmapped (UniProt)

Section 1

Recommended PPT1 IHC & IF Protocols

The catalog antibody’s IHC-P protocol (datasheet: M02690) is accompanied by published PPT1 IHC protocols for oral squamous cell carcinoma (PMC12767243) and hepatocellular carcinoma (PMC10314632).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Paraffin-embedded human intestinal cancer tissue; fixative not specified (datasheet M02690)
Fixation	Image fixative and duration unreported (datasheet M02690); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: EDTA pH 8.0 (datasheet M02690); 20 min, 95–100 °C (standard)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% goat serum (datasheet M02690)
Primary antibody	Mouse monoclonal (clone 10F3) anti-PPT1, 0.5-1μg/ml (datasheet M02690)
Primary incubation	Overnight at 4 °C (datasheet M02690)
Detection	Streptavidin-biotin complex (SABC), DAB chromogen (datasheet M02690)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	PPT1-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: General lysosomal expression. No signal in the no-primary control.

💡Decision noteStart with heat-mediated EDTA retrieval at pH 8.0 (datasheet: M02690). If optimizing retrieval, the oral carcinoma protocol reports microwave Tris–EDTA at pH 9.0 (PMC12767243).

Section 2

What Is the Expected PPT1 Staining Pattern?

PPT1 is a lysosomal protein that is also annotated in the Golgi apparatus, endoplasmic reticulum and secreted compartment; it has no transmembrane segment (UniProt P50897). In paraffin sections, expect intracellular staining in cell types with recorded PPT1 expression, including glandular cells, ciliated cells and glia (HPA tissue IHC). HPA rates the tissue pattern Supported, with medium consistency between staining and RNA data (HPA tissue IHC).

What am I looking at on my slide?
Granular cytoplasmic staining in adrenal or breast glandular cells, or bronchial ciliated cell bodies (HPA tissue IHC).	This fits the recorded High staining in those cells and the general lysosomal profile (HPA tissue IHC). Assess the cell body rather than requiring every cell or granule to stain equally (general IHC practice).
Cytoplasmic staining in caudate or cortical glia, or in Bergmann glia (HPA tissue IHC).	These are recorded High staining sites; Bergmann glia are described as cytoplasm/membrane positive (HPA tissue IHC). A membrane-associated component there should be judged alongside the intracellular pattern, rather than rejected on its own (HPA tissue IHC; UniProt P50897 localization).
Predominantly nuclear staining or a sharp surface-only outline without intracellular signal.	That distribution does not fit the reported lysosomal tissue profile or supported Golgi and vesicle IF localization (HPA tissue IHC; HPA subcellular ICC-IF). Treat it as suspect and check staining controls before assigning it to PPT1 (general IHC practice).
Strong signal in adipocytes or oral mucosal squamous cells, especially when expected positive cells are weak.	HPA records PPT1 as Not detected in those cell types (HPA tissue IHC). Check for cross-reactivity or endogenous chromogen-producing activity; an unexpected positive is not proof of either mechanism (general IHC practice).
Diffuse color across tissue and blank areas, or no signal in a known positive tissue.	Diffuse color limits compartment assessment; absent signal in an HPA High cell type makes the run inconclusive (HPA tissue IHC; general IHC practice). Compare no-primary and positive controls before interpreting either result (general IHC practice).

💡Expected PPT1 appearanceCall a positive result when intracellular, chiefly granular cytoplasmic staining is appreciable in HPA High glandular, ciliated or glial cells; isolated nuclear or widespread cell-free color is suspect (HPA tissue IHC; UniProt P50897 localization; general IHC practice).

How each factor affects the staining
Which tissue and cell type is being scored?	HPA reports low tissue specificity overall, yet its listed cells range from High to Not detected (HPA tissue IHC). Score the specified cell population, not the whole section: for example, adrenal glandular cells are High while adipocytes are Not detected (HPA tissue IHC).
Which intracellular pattern is supported?	UniProt lists lysosome, Golgi apparatus and endoplasmic reticulum, plus secretion, and reports no transmembrane segment (UniProt P50897). HPA describes general lysosomal tissue expression; its ICC-IF images support Golgi apparatus and vesicles (HPA tissue IHC; HPA subcellular ICC-IF). These sources do not require one identical pattern in every cell.
How strong is the antibody evidence?	The listed antibody HPA021546 is rated Supported for both IHC and ICC, and the tissue-level reliability is Supported with medium staining/RNA consistency (HPA antibodies; HPA tissue IHC). These ratings support a cautious pattern comparison; they do not establish that every unexpected stain is specific.
Do processing or glycosylation dictate retrieval?	PPT1 has a signal peptide at residues 1–27, a mature chain at 28–306, and three annotated glycosylation sites (UniProt P50897). Without an antibody epitope or target-specific fixation evidence, these facts cannot select a retrieval condition or predict fixation sensitivity (UniProt P50897; supplied source scope).
IF/ICC cross-check: what should appear?	HPA supports Golgi apparatus and vesicle localization in ICC-IF images from A-431 and U2OS cells (HPA subcellular ICC-IF). Use that observation as a localization cross-check for IF/ICC; it does not specify an IF protocol or replace the paraffin-section tissue pattern (HPA subcellular ICC-IF; HPA tissue IHC).

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
No stain in adrenal or breast glandular cells recorded as High (HPA tissue IHC).	A failed detection step, unsuitable antibody conditions or excessive background suppression are possibilities (general IHC practice); the HPA result alone does not identify the cause.	Check the run's positive control and detection reagents, then review retrieval and antibody conditions against the IHC-validated antibody's instructions (general IHC practice).
Color appears in no-primary controls or broadly outside cells.	Endogenous detection activity, nonspecific secondary binding or residual chromogen may contribute (general IHC practice).	Compare the no-primary control, check blocking appropriate to the detection system, and inspect reagent washes before scoring cellular PPT1 (general IHC practice).
Staining looks uniformly nuclear or sharply surface-only.	The compartment pattern conflicts with reported lysosomal tissue expression and supported Golgi/vesicle ICC-IF localization (HPA tissue IHC; HPA subcellular ICC-IF).	Recheck morphology and counterstain, compare a known positive cell population, and investigate antibody specificity before calling the signal PPT1 (general IHC practice).
Adipocytes or oral mucosal squamous cells stain strongly.	Those cells are Not detected in the HPA tissue observations; cross-reactivity or endogenous detection activity is possible (HPA tissue IHC; general IHC practice).	Compare no-primary controls and expected positive cells on the same run; report the unexpected staining as unresolved if controls cannot explain it (general IHC practice).
Signal is faint in one tissue but clear in another.	The recorded cell-level range includes High, Low and Not detected categories, while overall RNA specificity is low (HPA tissue IHC). A weak field alone cannot establish assay failure.	Identify the scored cell type and compare it with its HPA category; use a listed High cell type as the positive reference for that run (HPA tissue IHC; general IHC practice).
A retrieval change alters intensity or distribution.	Neither UniProt processing data nor HPA staining levels establish a PPT1-specific fixation or retrieval response (UniProt P50897; HPA tissue IHC).	Document both conditions and compare positive and no-primary controls under each; choose conditions by reproducible cellular pattern and controlled background (general IHC practice).

Source: UniProt P50897 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing PPT1 staining

IHC analysis of PPT1 using anti PPT1 antibody (M02690). PPT1 was detected in paraffin-embedded section of human intestinal cancer tissue. Heat mediated antigen retrieval was performed in EDTA buffer (pH8.0, epitope retrieval solution). The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1μg/ml mouse anti-PPT1 Antibody (M02690) overnight at 4°C. Biotinylated goat anti-mouse IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC) (Catalog # SA1021) with DAB as the chromogen.

M02690 · IHCIHC analysis of PPT1 using anti PPT1 antibody (M02690). PPT1 was detected in paraffin-embedded section of human intestinal cancer tissue. He

IHC analysis of PPT1 using anti PPT1 antibody (M02690). PPT1 was detected in paraffin-embedded section of human lung cancer tissue. Heat mediated antigen retrieval was performed in EDTA buffer (pH8.0, epitope retrieval solution). The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1μg/ml mouse anti-PPT1 Antibody (M02690) overnight at 4°C. Biotinylated goat anti-mouse IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC) (Catalog # SA1021) with DAB as the chromogen.

M02690 · IHCIHC analysis of PPT1 using anti PPT1 antibody (M02690). PPT1 was detected in paraffin-embedded section of human lung cancer tissue. Heat med

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000131238-PPT1/tissue/cerebral+cortex#imid_5775660

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000131238-PPT1/tissue/colon#imid_5775594

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000131238-PPT1/tissue/liver#imid_5775587

HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000131238-PPT1/tissue/kidney#imid_5775596

HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA021546; green = PPT1, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for PPT1 IHC & IF

🧪Run adrenal gland first: its glandular cells should stain for PPT1 (HPA: High in adrenal gland glandular cells). Use adipose tissue adipocytes as the negative tissue (HPA: Not detected in adipocytes); compare non-glandular cells on the adrenal slide for background staining, but do not assume they are PPT1-negative without validation (HPA: adrenal gland result specifies glandular cells).

Positive control tissue: Adrenal gland (Glandular cells, HPA High)

Negative control tissue: Adipose tissue (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show PPT1 in A-431, U2OS, with annotated localisation: Golgi apparatus (supported), Vesicles (supported) (HPA subcellular).

Technical controls: Include a no-primary, secondary-only control; a mouse immunoglobulin isotype control matched to the primary antibody’s class and clonality; and PPT1-knockout tissue as a biological negative (caption: mouse anti-PPT1 M02690; standard IHC practice). On adrenal sections, quench endogenous peroxidase and assess endogenous biotin background because the reported detection uses biotinylated secondary antibody, SABC and DAB (caption: biotinylated goat anti-mouse IgG, SABC/DAB; standard IHC practice).

⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected M02690 paraffin-section caption does not state the fixative (caption: fixative not stated). Start with heat retrieval in EDTA at pH 8.0, as reported for that IHC example; whether retrieval is required has not been established by the supplied evidence (caption: EDTA pH 8.0 heat retrieval). The supplied evidence does not establish that frozen sections or IF are easier; adrenal endogenous peroxidase or biotin background could complicate interpretation with the reported SABC/DAB detection (caption: SABC/DAB; standard IHC practice).

HPA tissue IHC evidence for PPT1

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Adrenal gland	Glandular cells	High	Protein (IHC)	HPA →
Breast	Glandular cells	High	Protein (IHC)	HPA →
Bronchus	Ciliated cells (cell body)	High	Protein (IHC)	HPA →
Caudate	Glial cells	High	Protein (IHC)	HPA →
Cerebellum	Bergmann glia - cytoplasm/membrane	High	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Adipose tissue	Adipocytes	Not detected	Protein (IHC)	HPA →
Cervix	Glandular cells	Not detected	Protein (IHC)	HPA →
Oral mucosa	Squamous epithelial cells	Not detected	Protein (IHC)	HPA →
Vagina	Squamous epithelial cells	Not detected	Protein (IHC)	HPA →

Section 3

Advanced PPT1 IHC Tips

Troubleshoot PPT1 staining in paraffin sections by checking retrieval, compartment, controls and cell-specific scoring before interpreting chromogenic signal.

How should I adjust retrieval when PPT1 staining is weak or uneven?

Start with heat-mediated retrieval in EDTA at pH 8.0 (datasheet M02690). The selected paraffin-section image used that retrieval before incubation with 1 µg/mL antibody overnight at 4°C (caption M02690). If staining is weak, first compare sections with consistent heating, cooling and reagent coverage; uneven retrieval can produce regional differences (standard IHC practice). If those checks fail, test an alternative retrieval condition on matched sections as a fallback, keeping detection and exposure to chromogen constant (standard IHC practice). Judge the result by cellular staining and preservation of morphology, rather than stronger DAB alone (standard IHC practice).

Could fixation explain faint PPT1 staining in my paraffin sections?

PPT1-specific sensitivity to fixation is unknown from the supplied evidence; the selected tissue caption says paraffin-embedded and does not state the fixative (caption M02690). Record the actual fixative, fixation duration and tissue-processing history before attributing weak staining to retrieval or antibody concentration (standard IHC practice). Compare similarly processed sections in the same staining run, using a documented positive cell population to check whether staining survived processing (standard IHC practice; HPA: high in adrenal glandular cells). If fixation histories differ, interpret intensity comparisons cautiously and assess morphology alongside staining, since processing differences can change antigen accessibility (standard IHC practice).

Where should convincing PPT1 staining appear within a positive cell?

Expect predominantly intracellular, vesicular staining consistent with lysosomal PPT1, while recognizing that PPT1 is also annotated as secreted and associated with the Golgi apparatus and endoplasmic reticulum (UniProt P50897 localisation). Supported immunofluorescence locations include the Golgi apparatus and vesicles (HPA subcellular). In chromogenic sections, check whether signal belongs to intact cell bodies and has a plausible punctate or perinuclear distribution; DAB alone cannot identify an organelle (standard IHC practice). Diffuse extracellular deposits or a sharp stained rim at the section edge need comparison with morphology and controls before being called PPT1 (standard IHC practice; UniProt P50897 localisation).

Can this antibody distinguish PPT1 isoforms or recognise processed PPT1?

The record lists 2 PPT1 isoforms and a precursor of 306 amino acids, with a signal peptide at residues 1–27 and a chain at 28–306 (UniProt P50897 processing and isoforms). It also lists glycosylation sites at residues 197, 212 and 232 (UniProt P50897 glycosylation). The supplied caption does not map the M02690 epitope or establish isoform selectivity (caption M02690). Check the antibody’s documented immunogen or epitope before making either claim, and interpret altered staining after retrieval as possible changes in epitope accessibility, not proof of a particular isoform or glycoform (standard IHC practice).

How can I investigate PPT1 localisation by multiplex IF?

For a separate IF experiment, pair PPT1 with a glial cell marker when examining cerebral cortex, where glial cells show high tissue staining (HPA: high in cerebral cortex glial cells; standard IF practice). Include a lysosomal or Golgi marker to assess compartment overlap, because PPT1 is annotated in lysosomes and the Golgi, and HPA supports Golgi and vesicle localisation (UniProt P50897 localisation; HPA subcellular). Choose spectrally separated fluorophores and consider a far-red PPT1 channel if tissue autofluorescence obscures shorter wavelengths (standard IF practice). For intracellular epitopes, optimise permeabilisation to admit antibodies across cellular and organelle membranes; the supplied evidence does not identify this antibody’s epitope or establish an IF protocol (UniProt P50897 topology; caption M02690).

What should I check when DAB obscures PPT1-positive cells?

Run a no-primary control and inspect whether brown signal persists, then review blocking, wash stringency and chromogen development together (standard IHC practice). The selected paraffin-section method used 10% goat serum, a biotinylated goat anti-mouse secondary and streptavidin–biotin detection with DAB (caption M02690). Include a peroxidase block in a chromogenic workflow, and assess whether the detection system contributes background independently of primary-antibody binding (standard IHC practice). Because PPT1 is associated with intracellular vesicles and lysosomes, score staining within identifiable cells; diffuse deposits, damaged areas and section edges require particular scrutiny (UniProt P50897 localisation; standard IHC practice).

How should I quantify PPT1 across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION

Define the cell population and tissue compartment before scoring, since PPT1 tissue staining varies by cell type (HPA tissue IHC). For comparable fields, record the percentage of positive target cells and staining intensity, or calculate an H-score from intensity categories 0–3 on a 0–300 scale (standard IHC practice). If the biological question concerns abundance of positive cells, report their density per mm² of viable tissue and normalise for sampled area (standard IHC practice). Keep acquisition, DAB development and thresholds consistent, exclude necrotic regions, and report staining by cell type rather than pooling every cell in a section (standard IHC practice).

How do I distinguish genuine PPT1 signal from an artefact?

Check for staining in intact cells with a plausible vesicular or perinuclear pattern, consistent with PPT1’s lysosomal and Golgi annotations (UniProt P50897 localisation; HPA subcellular). Compare cell identity with documented patterns: adrenal glandular cells and cerebral cortex glial cells are high, whereas adipocytes are reported as not detected (HPA tissue IHC). An abrupt edge effect, signal confined to necrosis, or staining reproduced in a no-primary control argues for artefact; residual endogenous peroxidase can also generate chromogenic background (standard IHC practice). Treat staining intensity as an observation rather than proof of PPT1 activity, and weigh conclusions against the HPA tissue-IHC reliability rating of Supported with medium RNA–staining consistency (HPA tissue IHC).

Boster reagents

Best PPT1 / Palmitoyl-protein thioesterase 1 IHC Antibodies

Human paraffin-section PPT1 IHC is shown for M02690 (catalog IHC caption); PB9781 lists human ICC, but provides no IF figure (catalog applications and image alts).

Real IHC data

Anti-PPT1 Antibody ® (monoclonal, 10F3)

Cat # M02690

View product →

M02690 will render with an IHC figure from a paraffin-embedded human intestinal cancer section (M02690 IHC caption). Its catalog also shows paraffin-section IHC in human lung and mammary cancer tissues (M02690 IHC captions).

Which to pick: Choose mouse monoclonal M02690 for human paraffin-section IHC: its figure uses EDTA retrieval at pH 8.0 and 1 μg/ml primary antibody; the fixative is unreported (M02690 catalog and IHC caption). For ICC, consider rabbit PB9781, which lists human ICC; neither SKU provides an IF figure (PB9781 applications; catalog image alts). PB9781 lists human, mouse and rat reactivity, but its paraffin-section IHC figure is human only, with citrate retrieval at pH 6; its fixative is unreported (PB9781 catalog and IHC caption).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry P50897 (PPT1_HUMAN, Palmitoyl-protein thioesterase 1).
Human Protein Atlas. PPT1 tissue IHC expression (reliability: Supported).
Human Protein Atlas. PPT1 subcellular location (ICC-IF): Localized to the Golgi apparatus and vesicles..
Human Protein Atlas. PPT1 antibody validation summary (1 antibodies).
High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma. Cancer cell international 2022 — PMC8917761.
Evaluating palmitoyl-protein thioesterase 1 in oral squamous cell carcinoma: A novel indicator of tumor behavior and therapeutic response. World journal of experimental medicine 2025 — PMC12767243.
Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma. Journal for immunotherapy of cancer 2023 — PMC10314632.
A prognostic model correlated with fatty acid metabolism in Ewing's sarcoma based on bioinformatics analysis. Open medicine (Warsaw, Poland) 2025 — PMC12355353.
PubMed PMID:7637805 — UniProt-cited evidence.
PubMed PMID:8633062 — UniProt-cited evidence.
PubMed PMID:8786130 — UniProt-cited evidence.